567 Results

People

  1. Motzer
    Motzer
  2. Horwitz
    Horwitz
  3. Riely
    Riely
  4. Zelenetz
    Zelenetz
  5. Kris
    Kris
  6. Postow
    Postow
  7. Rusch
    Rusch
  8. Wolchok
    Wolchok
  9. Bains
    Bains
  10. Giralt
    Giralt

Groups

  1. Department of Medicine (349)
  2. Solid Tumor Oncology Division (186)
  3. Hematologic Malignancies, Division of (140)
  4. Center for Hematologic Malignancies (120)
  5. Survivorship Research (74)
  6. Surgery (72)
  7. Division of Subspecialty Medicine (66)
  8. GSK Faculty (53)
  9. Thoracic Oncology (53)
  10. Lymphoma (48)
  1. "pneumonia"
Formats
  1. Journal Article (509)
  2. Review (36)
  3. Research Letter (5)
  4. Book Section (4)
  5. Editorial (4)
  6. Correspondence (3)
  7. Guidelines (3)
  8. Conference Paper (1)
  9. Meeting Abstract (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (349)
  2. Solid Tumor Oncology Division (186)
  3. Hematologic Malignancies, Division of (140)
  4. Center for Hematologic Malignancies (120)
  5. Survivorship Research (74)
  6. Surgery (72)

More Groups

People
  1. Robert Motzer (24)
  2. Jedd Wolchok (16)
  3. Steven Horwitz (15)
  4. Andrew Zelenetz (14)
  5. Gregory Riely (14)
  6. Mark Kris (12)

More People

Years
  1. 2025 (27)
  2. 2024 (54)
  3. 2023 (48)
  4. 2022 (24)
  5. 2021 (20)
  6. 2020 (40)

More Years

Publications
  1. Journal of Clinical Oncology (34)
  2. Lancet Oncology (23)
  3. Cancer (17)
  4. Blood (16)
  5. Journal of Thoracic Oncology (14)
  6. Blood Advances (13)

More Publications

Publishers
  1. Elsevier Inc. (105)
  2. Elsevier Science, Inc. (49)
  3. Springer (36)
  4. American Society of Clinical Oncology (35)
  5. Nature Publishing Group (35)
  6. Oxford University Press (34)

More Publishers

Results (567)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma
    Review

    Voorhees, P. M.; Sborov, D. W.; Laubach, J.; Kaufman, J. L.; Reeves, B.; Rodriguez, C.; Silbermann, R.; Costa, L. J.; Anderson, L. D. Jr; Nathwani, N.; more...
    Future Oncology (2025)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
    Journal Article

    Kumar, A.; Soumerai, J.; Abramson, J. S.; Barnes, J. A.; Caron, P.; Chhabra, S.; Chabowska, M.; Dogan, A.; Falchi, L.; Grieve, C.; more...
    Blood (2025)

    Fulltext@MSK | Save
  • MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: A phase I trial
    Journal Article

    Gounder, M.; Johnson, M.; Heist, R. S.; Shapiro, G. I.; Postel-Vinay, S.; Wilson, F. H.; Garralda, E.; Wulf, G.; Almon, C.; Nabhan, S.; more...
    Nature Communications (2025)

    Fulltext@MSK | Save
  • New treatments for adult T-cell leukemia/lymphoma
    Review

    Epstein-Peterson, Z. D.; Gurumurthi, A.; Horwitz, S. M.
    Leukemia Research (2025)

    Fulltext@MSK | Save
  • Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): A multiregional, randomised, double-blind, placebo-controlled, phase 3 study
    Journal Article

    Sangro, B.; Kudo, M.; Erinjeri, J. P.; Qin, S.; Ren, Z.; Chan, S. L.; Arai, Y.; Heo, J.; Mai, A.; Escobar, J.; more...
    Lancet (2025)

    Fulltext@MSK | Save
  • A phase II study of acimtamig (AFM13) in patients with CD30-positive, relapsed, or refractory peripheral T-cell lymphomas
    Journal Article

    Kim, W. S.; Shortt, J.; Zinzani, P. L.; Mikhailova, N.; Radeski, D.; Ribrag, V.; Domenech, E. D.; Sawas, A.; Alexis, K.; Emig, M.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6
    Journal Article

    Hughes, B. G. M.; Guminski, A.; Bowyer, S.; Migden, M. R.; Schmults, C. D.; Khushalani, N. I.; Chang, A. L. S.; Grob, J. J.; Lewis, K. D.; Ansstas, G.; more...
    Journal of the American Academy of Dermatology (2025)

    Fulltext@MSK | Save
  • Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): A multicentre, open-label, single-arm, phase 2 study
    Journal Article

    Zinzani, P. L.; Izutsu, K.; Mehta-Shah, N.; Barta, S. K.; Ishitsuka, K.; Córdoba, R.; Kusumoto, S.; Bachy, E.; Cwynarski, K.; Gritti, G.; more...
    Lancet Oncology (2024)

    Fulltext@MSK | Save
  • Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor-resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer
    Journal Article

    Yang, J. C. H.; Lee, D. H.; Lee, J. S.; Fan, Y.; de Marinis, F.; Iwama, E.; Inoue, T.; Rodríguez-Cid, J.; Zhang, L.; Yang, C. T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Atezolizumab monotherapy for metastatic urothelial carcinoma: Final analysis from the phase II IMvigor210 trial
    Journal Article

    Rosenberg, J. E.; Galsky, M. D.; Powles, T.; Petrylak, D. P.; Bellmunt, J.; Loriot, Y.; Necchi, A.; Hoffman-Censits, J.; Perez-Gracia, J. L.; van der Heijden, M. S.; more...
    ESMO Open (2024)

    Fulltext@MSK | Save